Immodulon appoints Josefine Roemmler-Zehrer as chief medical officer

Betsy Goodfellow | June 20, 2023 | Appointment | |  Immodulon, Josefine Roemmler-Zehrer, appointment, chief medical officer 

Cancer immunotherapy company Immodulon has announced that it has appointed Josefine Roemmler-Zehrer as chief medical officer, bringing with her vast experience in the clinical and medical affairs spheres.

Previously, Roemmler-Zehrer has held senior leadership positions at various leading pharmaceutical companies including Celgene, Amgen and Ipsen, having had successes in multiple product development programmes and leading multi-disciplinary teams in a range of therapeutic areas such as oncology, inflammation, rheumatology, dermatology, neurology and rare diseases.

Gertjan Barlema, chief executive officer of Immodulon, stated: “I am delighted to welcome incoming Josefine to the new leadership team at Immodulon as we prepare to advance our lead asset IMM-101 into a pivotal trial. Josefine brings a wealth of global experience in clinical and medical affairs from leading pharmaceutical companies and will be instrumental in our efforts to unlock the full potential of IMM-101. We look forward to benefitting from Josefine’s insights and leadership as we finalise the design of our pivotal trial in pancreatic cancer and advance our mission to improve the lives of patients suffering from this difficult to treat cancer.”

Commenting on her new role, Roemmler-Zehrer added: “I am so pleased to be joining Immodulon at this pivotal time in the company’s development. I have been excited and inspired by the new management’s energy and commitment to bring IMM-101, a new, transformative, broad spectrum immunotherapy to patients with pancreatic cancer. Pancreatic cancer has the highest mortality of any solid tumour and patients have few meaningful treatment options. I believe that IMM-101 can make a major contribution in addressing this fatal disease.”

Related Content


Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …


Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …


Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content